Evolus (NASDAQ:EOLS) Shares Down 5.7% - Here's What Happened

Evolus, Inc. (NASDAQ:EOLS - Get Free Report)'s stock price dropped 5.7% during mid-day trading on Monday . The company traded as low as $11.13 and last traded at $10.99. Approximately 154,100 shares were traded during mid-day trading, a decline of 77% from the average daily volume of 665,766 shares. The stock had previously closed at $11.65.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on EOLS shares. HC Wainwright reaffirmed a "buy" rating and set a $27.00 price objective on shares of Evolus in a research report on Thursday, April 10th. Barclays lifted their price objective on shares of Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Needham & Company LLC restated a "buy" rating and issued a $22.00 target price on shares of Evolus in a research note on Wednesday, April 9th. Finally, BTIG Research initiated coverage on Evolus in a research report on Thursday, April 17th. They set a "buy" rating and a $21.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Evolus presently has an average rating of "Buy" and an average target price of $23.75.

Evolus Stock Up 2.4 %

The company has a market capitalization of $778.81 million, a price-to-earnings ratio of -13.27 and a beta of 1.11. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. The business's 50 day moving average is $11.98 and its 200 day moving average is $12.74.

Insider Transactions at Evolus

In related news, Director Karah Herdman Parschauer sold 12,888 shares of Evolus stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $12.99, for a total transaction of $167,415.12. Following the completion of the sale, the director now owns 32,183 shares of the company's stock, valued at $418,057.17. The trade was a 28.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Rui Avelar sold 27,904 shares of the firm's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total transaction of $370,007.04. Following the transaction, the insider now directly owns 362,467 shares of the company's stock, valued at $4,806,312.42. This represents a 7.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 60,575 shares of company stock worth $794,369. Company insiders own 6.10% of the company's stock.

Institutional Trading of Evolus

A number of hedge funds and other institutional investors have recently made changes to their positions in EOLS. KBC Group NV purchased a new stake in Evolus in the fourth quarter valued at $49,000. IFP Advisors Inc lifted its holdings in shares of Evolus by 17,440.7% in the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock valued at $52,000 after buying an additional 4,709 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in shares of Evolus in the fourth quarter worth about $106,000. Rafferty Asset Management LLC acquired a new stake in Evolus during the fourth quarter worth about $115,000. Finally, Quantbot Technologies LP purchased a new position in Evolus during the fourth quarter valued at approximately $118,000. Institutional investors and hedge funds own 90.69% of the company's stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.